Background: E-proteins are transcription factors important for the development of a variety of cell types, including neural, muscle and lymphocytes of the immune system. E2A, the best characterized E-protein family member in mammals, has been shown to have stage specific roles in cell differentiation, lineage commitment, proliferation, and survival. However, due to the complexity of E2A function, it is often difficult to separate these roles using conventional genetic approaches. Here, we have developed a new genetic model for reversible control of E2A protein activity at physiological levels. This system was created by inserting a tamoxifen-responsive region of the estrogen receptor (ER) at the carboxyl end of the tcfe2a gene to generate E2AER fusion proteins. We have characterized and analyzed the efficiency and kinetics of this inducible E2A ER system in the context of B cell development.
Background
E2A, encoded by the tcfe2a gene and a member of the Eprotein family, is a basic helix-loop-helix (HLH) transcription factor critical for regulating gene expression in several developmental systems [1] . Originally identified as an immunoglobulin (Ig) enhancer binding factor, E2A has since largely been studied for its roles during the development of B and T lymphocytes [2, 3] . E2A partici-pates in various aspects of lymphocyte development including lineage commitment, initiation of lineage specific gene expression, rearrangement of B and T cell receptor genes, and differentiation through multiple developmental stages. In addition to roles in lineage commitment and cell differentiation, E2A has also been shown to regulate cell cycle, proliferation, and survival. E-proteins, including E2A, HEB, and E2-2 in mammals, function as dimers to bind DNA and regulate gene expression. E2A homodimers are the primary E-protein dimers functioning in B cells, whereas E2A-HEB heterodimers are the primary dimers functioning in T cells [4] [5] [6] . Recent data suggests that E2-2 homodimers are critical for plasmacytoid dendritic cell development [7, 8] . E2A also serves as an important dimerization partner for tissue specific HLH transcription factors outside of the lymphoid system. For example, E2A forms dimers with NeuroD and MyoD, key regulators of neuronal and skeletal muscle development, respectively [9] [10] [11] . Since E2A is the common factor for multiple lineage specific HLH transcription factor dimers, novel tools for targeting and manipulating E2A function can benefit a range of developmental biology research areas.
Here we have developed a new genetic model to examine E2A function. We have established an inducible E2A mouse model by inserting a tamoxifen-responsive region of the estrogen receptor (ER) ligand binding domain at the carboxyl end of tcfe2a, resulting in the production of E2AER fusion proteins. The use of tamoxifen inducible ER fusion proteins in mouse genetics has already been established as a valuable tool, especially with the vast use of the Cre recombinase-ER fusion protein for inducible gene knockout in mice [12] [13] [14] [15] . In addition, ER fusion with a variety of transcription factors has also been successfully employed for analysis of gene expression. For example, MyoD-ER fusion proteins have been expressed by viral transduction in mouse embryonic fibroblasts for in vitro study of MyoD gene regulation [16] and in mouse fibroblasts for analysis of MyoD activation in vivo post transplantation of transduced cells into recipient animals [17] . However, we do not know how useful the ER system will be in live animals when targeting an endogenous locus. Our E2A ER system now introduces an ER fusion with a bHLH transcription factor into the mouse genome for analysis of an endogenously expressed protein.
E2A ER/+ and E2A ER/ER mice, along with E2AER protein function, are analyzed here in the context of B cell development. A block in B cell development at the pre-proB cell stage, prior to B lineage commitment, has been characterized by previous E2A-deficient mouse models [18, 19] . A rescue in B cell development from E2A ER/ER pre-proB cells upon tamoxifen treatment would be a stringent test to verify inducible E2AER function.
In this study, we provide the initial characterization of the E2A ER system. E2AER protein activity was rapidly induced upon tamoxifen treatment and reversibly regulated by tamoxifen withdrawal. Even though we show effective induction of E2AER DNA binding activity, tamoxifen treatment of E2A ER/ER mice did not efficiently restore B cells in vivo. However, tamoxifen treatment was able to rescue and support early B cell development from E2A ER/ ER pre-proB cells in an ex vivo culture system. Use of E2A ER ex vivo culture systems may therefore be beneficial for the study of gene regulation in B cells and other E2A-regulated cell lineages.
Results
Generation of the E2A ER allele E2A ER/+ and E2A ER/ER mice were generated by using a knock-in strategy for tamoxifen-inducible E2A function. The tamoxifen-responsive ligand binding domain of the mouse ER [20] was inserted at the carboxyl end of tcfe2a to produce the E2A ER allele ( Figure 1A , B). With this targeting strategy, similar to that used for the E2A GFP strain previously developed in our lab [21] , both alternatively spliced products of the tcfe2a gene, E12 and E47, are translated as ER fusion proteins. Initial characterization of the E2A ER allele indicated normal expression levels of E2A mRNA in the presence of the ER insertion ( Figure 1C ). Previous study of E2A knockout mice has demonstrated stunted growth and a high lethality rate of homozygous animals within the first few weeks after birth [18, 19] . In contrast, the E2A E47bm strain, expressing a dominant negative form of E47, was originally described as indistinguishable from wild-type litter mates in size and survival [22] . However, this work was analyzing mice on a mixed genetic background. Upon backcrossing to C57BL/6, the E2A E47bm/E47bm mice became smaller in size and demonstrated the high lethality rate like that shown with the knockout animals (unpublished data). E2A ER/ER animals also exhibit stunted growth and reduced survival (see Additional file 1). Fortunately, the lethality rate in our experience has been less severe in litters from the E2A ER strain than that observed with our E2A knockout and dominant negative strains. However, we do not know if this slight increase in postnatal survival is due to the presence of the E2AER protein or because our E2A ER strain is currently on a mixed background.
The E2A ER allele resembles an E2A-deficient allele in the absence of ligand B cells develop from hematopoietic stem cells (HSC) in the bone marrow through a series of developmental stages [23] . The pre-proB cell stage is an intermediate stage as lymphoid progenitors develop into committed proB cells. Pre-proB cells can be characterized by the expression of B220 and CD43 and the absence of CD19 expression. As pre-proB cells transition to the proB cell stage, CD19 expression is induced and cells undergo commitment to the B cell lineage. E2A is critical for this transition, as demonstrated by the block in development at the pre-proB cell stage in E2A-deficient animals [18, 19, 24] . Analysis of E2A GFP mice displays the up-regulation of E2A protein levels from the pre-proB to proB stage (see Additional file 2) [21] . This increase in E2A expression is likely critical for E2A's regulation of the B cell lineage gene expression profile given the importance of E2A gene dosage. For example, elimination of one copy of E2A has been shown to greatly reduce the number of proB cells [4, 18] .
Investigation of B cell development in E2A ER/ER mice revealed a block at the pre-proB cell stage, similar to that seen in the E2A-mutant E2A E47bm/E47bm mice ( Figure 2A ) [22] . Occasionally we have observed a small population of CD19 + B cells in the bone marrow of E2A ER/ER mice, but these incidences of leaky B cell development did not appear to produce a significant population of mature, Ig expressing B cells ( Figure 2B ). Even though E2A has been suggested to influence proliferation in developing B cells [20, [25] [26] [27] , no significant difference in expansion at the pre-proB cell stage was observed by BrdU analysis of E2A ER/ER and wild-type mice (see Additional file 3).
For analysis of E2AER protein expression and DNA binding activity, we chose to derive Abelson transformed preB cells from E2A ER/+ and E2A ER/ER bone marrow [28] . E2AER protein expression was verified by Western Blot analysis of whole cell lysates from E2A ER/+ and E2A ER/ER Abelson cells ( Figure 3A ). While E2AER protein levels appeared similar to wild-type levels when comparing E2A +/+ and Generation of the E2A ER allele Whole cell lysates were collected from E2A +/+ , E2A -/-, E2A ER/+ , E2A ER/ER , and E2A GFP/GFP Abelson-transformed preB cell lines and analyzed by Western Blot for E2A protein expression using an anti-E2A antibody. E2A +/+ , E2A ER/+ , and E2A ER/ER Abelson cells were also cultured with tamoxifen prior to analysis, as indicated. E2A +/+ , E2A GFP/GFP , and E2A -/-lines were used as positive and negative controls for E2A proteins. ERK2 was used as a loading control. (B and C) Analysis of E2AER DNA binding activity. E2A ER/ER Abelson-transformed preB cells were cultured (B) without and with tamoxifen for 1, 6 and 10 hr and (C) with tamoxifen and upon tamoxifen withdrawal for 1 and 6 hr. Nuclear extracts were analyzed by gel shift for E2A DNA-binding using a μE5 probe. Anti-E2A antibody was used to demonstrate specificity (Ab). E2A-DNA complexes (arrow) and antibody-shifted complexes (arrow head) are indicated. *Non-specific band. Figure 3B) . Together, the block in B cell development and lack of E2AER DNA binding activity suggest that the E2A ER mouse model functions as an E2A-deficient system in the absence of ligand.
Rapid activation and reversible regulation of E2AER activity
Tamoxifen treatment of E2A ER/ER Abelson cells resulted in rapid E2AER DNA binding activity within 1 hr of treatment ( Figure 3B ). The specificity of the protein binding to the μE5 probe was verified by using an anti-E2A antibody that effectively super-shifted the protein/DNA complex. The effect of tamoxifen withdrawal was then tested by washing tamoxifen-treated cells and growing them in the absence of tamoxifen for 1 and 6 hr time points. Loss of E2AER DNA binding activity was seen within 6 hrs of tamoxifen withdrawal ( Figure 3C ), indicating relatively fast reversibility of E2A function. These results demonstrate that the E2A ER model can be used not only as an inducible model, but this system may also be valuable for providing a tightly regulated window of E2A activity.
Induction of E2AER activity supports early B cell development ex vivo
We first tested for a functional outcome of E2A induction by in vivo tamoxifen treatment of E2A ER/ER mice followed by analysis of B cell populations in the bone marrow and spleen. All in vivo treatment efforts, including intraperitoneal injection and treatment in drinking water, unfortunately resulted in low efficiency rescue of B cell development. The emergence of B cells in tamoxifentreated animals was rarely great enough to determine if the resulting B cells were generated in response to the tamoxifen treatment or were simply the incidence of leaky B cell development described above. The most significant recovery of B cells observed from in vivo treatment, which resulted from a 27 day tamoxifen treatment, was still considerably less than the B cell population in control mice ( Figure 4A, B) . However, the presence of Ig μ heavy chain (IgM) positive B cells in the spleen does suggest that a low level of tamoxifen-dependent B cell development occurred in vivo.
In contrast to in vivo tamoxifen treatment, treatment in an ex vivo B cell culture system effectively rescued the development of CD19 + B cells. Sorted E2A ER/ER pre-proB cells were cultured in hormone-free media on an S17 stromal layer in the presence of IL-7, with or without tamoxifen. Control DMSO treated E2A ER/ER pre-proB cells failed to develop efficiently into CD19 + B cells over the course of 5 days, whereas tamoxifen treated E2A ER/ER pre-proB cells effectively gave rise to CD19 + B cells ( Figure 5A ). Interestingly, the kinetics of B cell development from tamoxifen treated E2A ER/ER pre-proB cells appeared delayed compared to that of control cells. In addition to using CD19 expression to validate the rescue of B cell development, we analyzed Pax5 expression throughout the 5 day culture. Pax5, initiated downstream of E2A expression, is a transcription factor critical for B cell lineage commitment [29] . Consistent with CD19 expression, induction of Pax5 expression was observed in tamoxifen treated E2A ER/ER pre-proB cells, also appearing delayed compared to control cultures ( Figure 5B ).
Another key event during early B cell development, downstream of E2A function, is rearrangement of the Ig heavy chain locus (IgH) [2, 18, 19] . We next used this culture system to determine if induction of E2AER activity could also support IgH V to DJ recombination. To amplify V to DJ rearrangements, we chose primers recognizing members of the V H 1 gene family [30] , which represent a large percentage of the total IgH V genes, and primers recognizing the J H 4 gene segment. Rearrangements were analyzed in Day 8 cultured samples because we did not observe consistent V to DJ PCR signals until this point in the time course analysis. Wild-type mice were used as positive controls for detecting recombination events, and mice deficient in the recombination activating gene RAG1, required for V(D)J recombination, were used as negative controls.
Analysis of Day 8 cultures demonstrated a clear V to DJ rearrangement product from tamoxifen treated E2A ER/ER cells ( Figure 6 ). V to DJ rearrangement was further verified by sequencing analysis (see Additional file 4). The faint product detected from DMSO control treated E2A ER/ER cells was accompanied by a small "leaky" CD19 + population generated at this relatively late time point in the culture system (see Additional file 5). However, only one unique rearrangement product was identified out of all of the colonies sequenced for this sample. In addition to providing functional proof of induced E2A activity, the detection of IgH recombination, along with the induction of CD19 and Pax5 expression described above, suggests that restored E2A function can rescue B cell development from the pre-proB cell stage.
Discussion
The E2A ER system provides an improved method for analyzing E2A function. Previous analysis using over-expression of E2AER fusion proteins by retroviral transduction has already demonstrated the value of inducible E2A Tamoxifen-treated
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Tamoxifen treatment restores B cell development from E2A ER/ER pre-proB cells activity [20, [31] [32] [33] [34] . However, toxicity is often a problem with high levels of E2A in the cell [20, 35] , and viral transduction is not ideal for all cell types. In addition, the changes in gene expression detected upon over-expression of E2A may not always be representative of endogenous E2A function. Therefore, generation of the E2A ER allele provides an attractive system for studying gene regulation and other E2A-regulated events in potentially any E2A-expressing cell type at a more physiological level.
Here we demonstrate the rapid induction of E2AER DNA binding activity upon tamoxifen treatment and its potential for reversible function upon tamoxifen withdrawal. Figure 3A ) suggested that the E2AER protein level may also have been contributing to the delayed kinetics. In this sample, the E2AER band appeared less intense than the wild-type E2A band. However, it is not possible to determine from this analysis if the lower intensity was a result of reduced protein levels or variation in antibody affinity for the E2AER versus wild-type E2A protein. In addition, there was not a striking difference between the E2AER and wild-type protein levels when comparing the E2A +/+ and E2A ER/ER samples. Further investigation of tamoxifen treated E2A ER/ER preproB cells will be necessary to understand why the delayed detection of CD19 + B cells was observed.
Our ex vivo culture data clearly indicated a rescue of early B cell development to the proB cell stage. However, we have so far been unable to determine if tamoxifen treatment can rescue E2A ER/ER B cells through the subsequent preB cell stage, when E2A is known to be critical for Ig kappa light chain (Igk) recombination [38] . We were unable to test for induction of Igk recombination or surface IgM expression by using our ex vivo culture system because this system primarily supports development at a stage prior to these events (see Additional file 5 and data not shown). The presence of the small, but increased, population of E2A ER/ER IgM + B cells in the in vivo treatment experiment ( Figure 4A ) is the only current evidence suggesting tamoxifen-induced E2AER activity may be able to rescue B cell development to maturity. Additional B cell culture systems would be necessary to determine if tamoxifen treatment can rescue later stages of E2A ER/ER B cell development.
While in vivo tamoxifen treatment was not efficient for restoring B cell development, in vivo treatment may still be useful for analysis of E2A function in other cell lineages. We suggest two reasons for ineffective rescue of in vivo B cell development. First, progression through several stages of lymphocyte development is known to be dependent on proper E-protein dosage [4, 6, 18, 26, 39, 40] , and it is possible that the required E2A threshold is not maintained during our in vivo treatment for rescue of B cell development. For example, as mentioned above, we do not know if E2A ER/ER cells can sufficiently progress through the preB cell stage of development. Second, E2A has been suggested to be important for B cell survival [41] . Therefore, it is conceivable that even if B cells are rescued by tamoxifen treatment, they may be lost if E2AER activity is not maintained throughout the treatment.
IgH recombination detected upon culture of tamoxifen treated E2A ER/ER pre-proB cells Figure 6 IgH recombination detected upon culture of tamoxifen treated E2A ER/ER pre-proB cells. DNA was analyzed for IgH V to DJ rearrangements from Day 8 cultured wild-type (WT), Rag1 -/-(Rag) and E2A ER/ER (ER) preproB cells using V H 1 and J H 4 primers. Cells were cultured in hormone-free media on S17 stromal cells with IL-7 and tamoxifen (T) or DMSO (D). V-DJ rearrangement products using V H 1 family gene segments and J H 4 are shown. WT and Rag were used as positive and negative controls, respectively. No products were detected when using dH 2 O as an additional negative control (data not shown). CD14 was used to demonstrate DNA loading. This result is representative of 4 independent nested PCR reactions. 
Methods
Mice E2A E47bm mice have been described previously [22] . Generation of the E2A ER allele is described below. All research with mice was performed in accordance with relevant guidelines, and protocols were approved by the Duke University Animal Care and Use Committee.
Generation of the E2AER allele
The gene targeting strategy used was a modification of the strategy for generation of the E2A GFP strain [21] . The tamoxifen-responsive region of the mouse estrogen receptor ligand binding domain containing the G525R mutation [44] was PCR amplified from the MigR1-E47R vector [20] using the primers ERfpA: 5'-CGGATCCACGAAAT-GAAATGGGTGC-3' and ERrpA: 5'-CCGGCCGCTAGAAT-TCGATCGTGTTGGGGAAGCCCTC-3' to introduce a 5' BamHI site and 3' EcoRI and EagI sites for subsequent cloning steps. The ER fragment was inserted, replacing EGFP, at the BamHI position in frame with E2A. The targeting construct also contained a positive selection marker, PGKNeo cassette, and a negative selection marker, PGK driven thymidine kinase (TK) cassette. Mouse ES cells used were derived from a 129/sv strain obtained from Phillippe Soriano's lab in 1995 and then maintained in our own lab. E2A ER/+ and E2A ER/ER mice were maintained on a C57BL6 and 129/sv mixed background. Three primers were used for detection of wildtype and mutant alleles, yz164: 5'-AAGAACGAGGCCT-TCCGTGTC-3', yz29: 5'-TCGCAGCGCATCGCCTTCTA-3', and bjE2Ar3: 5'-CAAGAGACTAGGATGCCACTG-3'.
RT-PCR
RNA extraction, DNase I treatment and reverse transcription have been described previously [41] . Quantitative real-time PCR analysis for Pax5 expression was performed using a Roche LightCycler and Fast-Start DNA master SYBR green kit I (Roche) as per manufacturer's instructions. The following primers were used, E2A: f1 5'-CCAGTCTCAGAGAATGGCAC-3' and r1 5'-CCTTCGCTG-TATGTCCGGCTAG-3'; Pax5 and GAPDH primers [41] . Tamoxifen preparation for in vitro culture treatment Tamoxifen (Sigma) was prepared as a 1 mM stock (1000×) dissolved in cell culture grade dimethyl sulfoxide (DMSO) and stored at -20°C.
Cell staining and flow-cytometry

Abelson transformed preB cells
The E2A ER/ER Abelson preB cell line was derived by Abelson Murine Leukemia Virus transformation of bone mar-row cells from an E2A ER/ER mouse. Briefly, whole bone marrow was plated on an S17 stromal layer in the presence of 1 uM tamoxifen and 10 ng/mL IL-7 in 5% FBS RMPI media. This culture was performed prior to transduction to ensure cells were proliferating and were at the optimal target stage for Abelson transformation. Once an expanding B cell population was observed, cells were infected with Abelson virus in the presence of 4 ug/mL polybrene. Abelson transformed cells were then removed from the stromal layer, and tamoxifen and IL-7 were withdrawn. The established E2A ER/ER Abelson preB cell line was maintained in 10% FBS RPMI media (also containing 100 units/ml penicillin, 100 ug/mL streptomycin and 55 uM 2-mercaptoethanol) prior to experimental analysis. Additional Abelson lines were established as described previously [32] .
Western Blot
Abelson preB cell lines were cultured without tamoxifen or with 1 uM tamoxifen for 24 hr prior to analysis. Cells were lysed in RIPA lysis buffer (1% Triton, 0.5% sodium deoxycholic acid, 0.1% SDS, 25 mM Tris-Cl pH 7.6, 150 mM NaCl, 5 mM EDTA) with protease inhibitors. Whole cell lysates were resolved by SDS-PAGE and blotted with anti-E2A (G127-32, BD Biosciences, 554077) and anti-ERK2 (C-14, Santa Cruz Biotechnology, sc-154) antibodies.
Electrophoretic mobility shift assay E2A ER/ER Abelson preB cells were cultured with or without 1 uM tamoxifen as indicated. For withdrawal analysis, tamoxifen-treated cells were washed and re-plated in the absence of tamoxifen for the indicated times. Nuclear extracts were incubated with a 32 P-labeled μE5 oligonucleotide probe, with or without Yae anti-E2A monoclonal antibody (Santa Cruz Biotechnology, sc-416), and resolved on a 5% polyacrylamide gel. Gels were dried and exposed to a phosphor screen for phosphorimager analysis (Amersham Biosciences). Oligos used for μE5 probe: 5'-TCGAAGAACACCTGCAGCAGCT-3' and 5'-TAGAGCT-GCTGCAGGTGTTCTT-3'.
In vivo tamoxifen treatment
Mice were treated with tamoxifen in the drinking water for 27 days. A 68 mg/mL tamoxifen in ethanol stock was used to bring the concentration in drinking water to approximately 26 ug/mL, resulting in 0.04% ethanol in water. A fresh bottle of tamoxifen water was given every 5 days.
Ex vivo pre-proB culture system Sorted pre-proB cells were plated on an S17 stromal layer in 24-well plates at approximately 1.5 × 10 4 cells per well and cultured with 5% FBS RPMI hormone-free media containing 10 ng/mL IL-7. Hormone free media consisted of phenol-red free RPMI 1640 supplemented with 5% charcoal/dextran treated FBS (Hyclone), 100 units/mL penicillin, 100 ug/mL streptomycin, and 55 uM 2-mercaptoethanol. Treated wells contained 1 uM tamoxifen and untreated controls were given DMSO alone (0.1%). Cells received fresh media, cytokine, and tamoxifen or DMSO every other day. Cells were harvested at time points indicated, and samples were split in half for FACS analysis and RNA or DNA extraction.
IgH rearrangement analysis
Sorted pre-proB cells were ex vivo cultured as described above. DNA was extracted from Day 8 cultures and then analyzed for IgH V to DJ rearrangements using V H 1 gene family and J H 4 specific primers. A nested PCR strategy was used to amplify rearrangements involving V H 1 family gene segments. The following primers were used for Round 1: V H 1 ext 5'-AGRTYCAGCTGCARCAGTCT-3' [30] and J H 4 YZB6 5'-TCCCTCAAATGAGCCTCCAAAGTCC-3' [45] and for Round 2: V H 1 int 5'-GARGATRTCCTGYAAG-GCTTC -3' [30] and J H 4 YZB5 5'-CCTGAGGAGACGGT-GACTGAGGTTCCTTG-3' [46] . CD14 primers were used to demonstrate the presence of DNA in all samples [41] . V H 1-D H J H 4 PCR products were cloned into a pCR4 TOPO vector (Invitrogen) and sequenced (Direct Sequencing from Colonies Service, Eton Bioscience, Inc). Rearrangement product sequences were analyzed by SoDA [47] .
